BACKGROUND: Tenofovir is associated with renal proximal tubule injury. Such toxicity has not been extensively studied in HIV-1-infected children, in whom tenofovir is increasingly used. METHODS: History, urine and blood were collected at regular intervals from 448 children and adolescents with perinatal HIV-1 infection followed in the Pediatric HIV/AIDS Cohort study. Relationships between tenofovir use and proteinuria and chronic kidney disease (CKD) outcomes were examined using multivariable logistic regression models. Proteinuria was defined as at least one urine protein/creatinine ratio (uPCR) ≥ 0.2, and CKD as ≥ 2 sequential uPCR ≥ 0.2 or estimated glomerular filtration rates <60 mL/min/1.73 m with no subsequent resolution, or a clinical diagnosis not contradicted by a normal uPCR. Subjects with ≥ 2 uPCR <0.2, and no abnormal uPCR and eGFR comprised the comparison group. RESULTS: Subjects were 47% male, 72% black, 24% Hispanic, with entry mean age (± standard deviation) of 11.5 ± 2.5 years. Proteinuria prevalence at entry, and annually during 3 years, ranged from 10.3% to 13.7%. The cumulative prevalence of proteinuria was 22% (94/434, 95% confidence interval: 18%-26%) and CKD 4.5% (20/448, 95% confidence interval: 2.7%-6.8%). Duration of tenofovir use was an independent predictor of proteinuria, with >3 years of exposure having the highest risk compared with no exposure (odds ratio: 2.53, 95% confidence interval: 1.23-5.22, overall P = 0.01). Overall, duration of tenofovir use did not significantly predict the presence of CKD. CONCLUSIONS: Rates of proteinuria and CKD were lower than those seen in the pre-highly active antiretroviral therapy era. However, prolonged exposure to tenofovir increases risk of renal injury.
BACKGROUND:Tenofovir is associated with renal proximal tubule injury. Such toxicity has not been extensively studied in HIV-1-infectedchildren, in whom tenofovir is increasingly used. METHODS: History, urine and blood were collected at regular intervals from 448 children and adolescents with perinatal HIV-1 infection followed in the Pediatric HIV/AIDS Cohort study. Relationships between tenofovir use and proteinuria and chronic kidney disease (CKD) outcomes were examined using multivariable logistic regression models. Proteinuria was defined as at least one urine protein/creatinine ratio (uPCR) ≥ 0.2, and CKD as ≥ 2 sequential uPCR ≥ 0.2 or estimated glomerular filtration rates <60 mL/min/1.73 m with no subsequent resolution, or a clinical diagnosis not contradicted by a normal uPCR. Subjects with ≥ 2 uPCR <0.2, and no abnormal uPCR and eGFR comprised the comparison group. RESULTS: Subjects were 47% male, 72% black, 24% Hispanic, with entry mean age (± standard deviation) of 11.5 ± 2.5 years. Proteinuria prevalence at entry, and annually during 3 years, ranged from 10.3% to 13.7%. The cumulative prevalence of proteinuria was 22% (94/434, 95% confidence interval: 18%-26%) and CKD 4.5% (20/448, 95% confidence interval: 2.7%-6.8%). Duration of tenofovir use was an independent predictor of proteinuria, with >3 years of exposure having the highest risk compared with no exposure (odds ratio: 2.53, 95% confidence interval: 1.23-5.22, overall P = 0.01). Overall, duration of tenofovir use did not significantly predict the presence of CKD. CONCLUSIONS: Rates of proteinuria and CKD were lower than those seen in the pre-highly active antiretroviral therapy era. However, prolonged exposure to tenofovir increases risk of renal injury.
Authors: Ali Judd; Katherine L Boyd; Wolfgang Stöhr; David Dunn; Karina Butler; Hermione Lyall; Mike Sharland; Delane Shingadia; Andrew Riordan; Di M Gibb Journal: AIDS Date: 2010-02-20 Impact factor: 4.177
Authors: Hassane Izzedine; Jean Sebastien Hulot; Daniel Vittecoq; Joel E Gallant; Schlomo Staszewski; Vincent Launay-Vacher; Andrew Cheng; Gilbert Deray Journal: Nephrol Dial Transplant Date: 2005-03-01 Impact factor: 5.992
Authors: Christopher I Esezobor; Edna Iroha; Elizabeth Onifade; Adebola O Akinsulie; Edamisan O Temiye; Chinyere Ezeaka Journal: J Trop Pediatr Date: 2009-09-30 Impact factor: 1.165
Authors: Charles D Mitchell; Miriam C Chernoff; George R Seage; Murli U Purswani; Hans M L Spiegel; Gaston Zilleruelo; Carolyn Abitbol; Barbara Heckman; Christopher B Ponce; James M Oleske Journal: Pediatr Nephrol Date: 2014-08-24 Impact factor: 3.714
Authors: Cristina B Hofer; D Robert Harris; Ricardo Hugo de Oliveira; Thalita F de Abreu; Fabiana Kakehasi; Jose Henrique Pilotto; Noris Pavia Ruz; Margot R Krauss; Rohan Hazra Journal: AIDS Res Hum Retroviruses Date: 2014-07-16 Impact factor: 2.205
Authors: Aylin B Unsal; Aviva S Mattingly; Sara E Jones; Julia B Purdy; James C Reynolds; Jeffrey B Kopp; Rohan Hazra; Colleen M Hadigan Journal: J Clin Endocrinol Metab Date: 2017-08-01 Impact factor: 5.958
Authors: Sarah K Himes; Julia W Wu; Denise L Jacobson; Katherine Tassiopoulos; Rohan Hazra; Deborah Kacanek; Russell B Van Dyke; Kenneth C Rich; George K Siberry; Marilyn A Huestis Journal: Pediatr Infect Dis J Date: 2015-08 Impact factor: 2.129
Authors: Flávia Vanesca Felix Leão; Regina Célia de Menezes Succi; Daisy Maria Machado; Aída de Fátima Thomé Barbosa Gouvêa; Fabiana Bononi do Carmo; Suenia Vasconcelos Beltrão; Maria Aparecida de Paula Cançado; João Tomas de Abreu Carvalhaes Journal: Pediatr Nephrol Date: 2015-12-04 Impact factor: 3.714